A drug-drug interaction knowledge assessment instrument for health professional students: A Rasch analysis of validity evidence

Research in Social and Administrative Pharmacy

Volumn 7, Issue 1, 2011, Pages 16-26

  Warholak, Terri L ^a   Menke, J Michael ^a   Hines, Lisa E ^a   Murphy, John E ^a   Reel, Sally ^b   Malone, Daniel C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF NURSING   (United States)

Author keywords

Drug interaction; Education; Health professional student; Rasch

Indexed keywords

ARTICLE; ATTITUDE TO HEALTH; DRUG INTERACTION; EDUCATION; HUMAN; MEDICAL STUDENT; METHODOLOGY; NURSING STUDENT; PHARMACY STUDENT; REPRODUCIBILITY; VALIDATION STUDY;

DRUG INTERACTIONS; EDUCATIONAL MEASUREMENT; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; REPRODUCIBILITY OF RESULTS; STUDENTS, MEDICAL; STUDENTS, NURSING; STUDENTS, PHARMACY;

EID: 79952700768     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2010.01.001     Document Type: Article

References (67)

1. Hamilton R.A., Briceland L.L., Andritz M.H. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998, 18(5):1112-1120.
2. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003, 289(13):1652-1658.
3. Bader M.B. Role of ciprofloxacin in fatal seizures. Chest 1992, 101(3):883-884.
4. Ferrer-Dufol A., Perez-Aradros C., Murillo E.C., Marques-Alamo J.M. Fatal serotonin syndrome caused by moclobemide-clomipramine overdose. J Toxicol Clin Toxicol 1998, 36(1-2):31-32.
5. Gabb G.M. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug. Med J Aust 1996, 164(11):700-701.
6. Otte W., Birkenhager T.K., van den Broek W.W. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry 2003, 18(5):264-265.
7. Steuer A., Gumpel J.M. Methotrexate and trimethoprim: a fatal interaction. Br J Rheumatol 1998, 37(1):105-106.
8. Lafata J.E., Schultz L., Simpkins J., et al. Potential drug-drug interactions in the outpatient setting. Med Care 2006, 44(6):534-541.
9. Malone D.C., Hutchins D.S., Haupert H., et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005, 62(19):1983-1991.
10. Glassman P.A., Simon B., Belperio P., Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002, 40(12):1161-1171.
11. Ko Y., Malone D.C., Skrepnek G.H., et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008, 31(6):525-536.
12. Blix H.S., Viktil K.K., Moger T.A., Reikvam A. Identification of drug interactions in hospitals-computerized screening vs. bedside recording. J Clin Pharm Ther 2008, 33(2):131-139.
13. Cavuto N.J., Woosley R.L., Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996, 275(14):1086-1087.
14. Weideman R.A., Bernstein I.H., McKinney W.P. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999, 56(15):1524-1529.
15. Saverno K.R., Malone D.C., Kurowsky J. Pharmacy students' ability to identify potential drug-drug interactions. Am J Pharm Educ 2009, 73(2):27.
16. Tsuruoka S., Kawaguchi A., Harada K., Fujimura A. Favorable effect on postgraduate clinical practice of a drug-interaction exercise for undergraduate students. Eur J Clin Pharmacol 2006, 62(7):571-576.
17. Trujillo J. Instructional design and assessment: a drug interactions course. Am J Pharm Educ 2009, 73(4):1-8.
18. Isaac T., Weissman J.S., Davis R.B., et al. Overrides of medication alerts in ambulatory care. Arch Intern Med 2009, 169(3):305-311.
19. Lin C.P., Payne T.H., Nichol W.P., Hoey P.J., Anderson C.L., Gennari J.H. Evaluating clinical decision support systems: monitoring CPOE order check override rates in the Department of Veterans Affairs' Computerized Patient Record System. J Am Med Inform Assoc 2008, 15(5):620-626.
20. Murphy J.E., Forrey R.A., Desiraju U. Community pharmacists' responses to drug-drug interaction alerts. Am J Health Syst Pharm 2004, 61(14):1484-1487.
21. Weingart S.N., Toth M., Sands D.Z., Aronson M.D., Davis R.B., Phillips R.S. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003, 163(21):2625-2631.
22. Ko Y., Malone D.C., D'Agostino J.V., et al. Potential determinants of prescribers' drug-drug interaction knowledge. Res Social Adm Pharm 2008, 4(4):355-366.
23. Malone D.C., Abarca J., Hansten P.D., et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc (2003) 2004, 44(2):142-151.
24. Murphy J.E., Malone D.C., Olson B.M., Grizzle A.J., Armstrong E.P., Skrepnek G.H. Development of computerized alerts with management strategies for 25 serious drug-drug interactions. Am J Health Syst Pharm 2009, 66(1):38-44.
25. Battistella M., Mamdami M.M., Juurlink D.N., Rabeneck L., Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005, 165(2):158-160.
26. Knijff-Dutmer E.A., Schut G., Van de Laar M.A. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother 2003, 37(1):12-16.
27. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993, 153(14):1665-1670.
28. Webb D.J., Freestone S., Allen M.J., Muirhead G.J. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999, 83(5A):21C-28C.
29. Hansten P., Horn J.R. The Top 100 Drug Interactions. A Guide to Patient Management 2009, H & H Publications. LLP, Freeland, WA.
30. Hansten P.D., Horn J.R. Drug Interactions Analysis and Management 2008, Wolters Kluwer Health, St. Louis, MO.
31. Hansten P.D., Horn J.R., Hazlet T.K. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc 2001, 41(2):161-165.
32. Validity. The American Educational Research Association, the American Psychological Association, and the National Council on Measurement in Education. Standards for Educational and Psychological Testing 1999, 9-24. Joint Committee on Standards for Educational and Psychological Testing of the American Educational Research Association, the American Psychological Association, and the National Council on Measurement in Education, American Educational Research Association, Washington, DC.
33. Cronbach L.J., Meehl P.E. Construct validity in psychological tests. Psychol Bull 1955, 52:281-302.
34. Downing S.M. Threats to the validity of locally developed multiple-choice tests in medical education: construct-irrelevant variance and construct underrepresentation. Adv Health Sci Educ Theory Pract 2002, 7:235-241.
35. Messick S. Validity. Educational Measurement 1989, 13-103. Chapter 2, American Council on Education, MacMillan Publishing Company, New York, NY. 3rd ed. R.L. Linn (Ed.).
36. Messick S. The interplay of evidence and consequences in the validation of performance assessments. Educ Researcher 1994, 23:13-23.
37. Nunnally J.C., Bernstein I.H. Validity 1994, Vol. 83-113. McGraw-Hill, Inc., New York, NY.
38. Draugalis J.R., Jackson T.R. Objective curricular evaluation: applying the Rasch model to a cumulative examination. Am J Pharm Educ 2004, 68(2). Article 35.
39. Colliver J.A., Williams R.G. Technical issues: test application. Acad Med 1993, 68(6):454-463.
40. Smith E.V. Evidence for the reliability of measures and validity of measure interpretation: a Rasch measurement perspective. J Appl Meas 2001, 2(3):281-311.
41. Jackson T.R., Draugalis J.R., Slack M.K., Zachry W.M., D'Agostino J. Validation of authentic performance assessment: a process suited for Rasch modeling. Am J Pharm Educ 2002, 66(3):233-242.
42. Briggs A.L., Jackson T.R. The development and performance validation of a tool to assess patient anticoagulation knowledge. Res Social Adm Pharm 2005, 1(1):40-59.
43. Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests 1980, Danish Institute for Educational Research, Copenhagen, Denmark, Reprinted, University of Chicago Press.
44. Wright B.D., Stone M.H. The measurement model. Best Test Design: Rasch Measurement 1979, 1-24. Mesa Press, Chicago IL. B.D. Wright, M.H. Stone (Eds.).
45. Wright B., Panchapakesan N. A procedure for sample free item analysis. Educ Psychol Meas 1969, 29:23-48.
46. Hambleton R.K., Swaminathan H., Rogers H.J. Fundamentals of Item Response Theory 1991, Sage Publications, Newbury Park, CA, pp. 99-107.
47. Laio P.M., Campbell S.K. Examination of the item structure of the Alberta infant motor scale. Pediatr Phys Ther 2004, 16(1):31-38.
48. Pesudovs K., Garamendi E., Keeves J.P., Elliot D.B. The Activities of Daily Vision Scale for cataract surgery outcomes: re-evaluating validity with Rasch analysis. Invest Ophthalmol Vis Sci 2003, 44(7):2892-2899.
49. Duncan P.W., Bode R.K., Lai S.M., Perera S. Rasch analysis of a new stroke-specific outcome scale: the Strome Impact Scale. Arch Phys Med Rehabil 2003, 84:950-963.
50. O'Connor R.J., Cano S.J., Thompson A.J., Hobart J.C. Exploring rating scale responsiveness: does the total score reflect the sum of its parts?. Neurology 2004, 62(10):1842-1844.
51. McHorney C.A., Tarlov A.R. Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res 1995, 4(4):293-307.
52. Lai S.M., Perera S., Duncan P.W., Bode R. Physical and social functioning after stroke: comparison of the Stroke Impact Scale and Short Form-36. Stroke 2003, 34(2):488-493.
53. Wright B.D., Stone M.H. Best Test Design: Rasch Measurement 1979, Mesa press, Chicago, IL.
54. SPSS [computer program]. Chicago 2003.
55. Linacre B. Winsteps Computer Program 2008, [computer program], MESA Press, Chicago, IL.
56. Wright B., Linacre J.M. Reasonable mean-square fit values. Rasch Meas Trans 1994, 8(3):370.
57. Wright B., Stone M.H. Judging misfit. Making Measures 2004, 19-33. The Phaneron Press, Chicago, IL. B. Wright, M.H. Stone (Eds.).
58. Wright B. Diagnosing misfit. Rasch Meas Trans 1991, 5(2):18.
59. Smith R.M. Item analysis in the Rasch model. IPARM: Item and Person Analysis With the Rasch Model 1991, 164-181. MESA Press, Chicago, IL. R.M. Smith (Ed.).
60. Linacre J.M., Wright B. Interpreting output tables. A User's Guide to BIGSTEPS WINSTEPS Rasch Model Computer Program 2001, 94-115. MESA Press, Chicago, IL. J.M. Linacre, B. Wright (Eds.).
61. Abarca J., Malone D.C., Armstrong E.P., et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003) 2004, 44(2):136-141.
62. Chao S.D., Maibach H.I. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005, 6(2):105-111.
63. Fulda T.R., Valuck R.J., Zanden J.V., Parker S., Byrns P.J. Commentary: disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res 2000, 61(8):540-548. Panel TUPDURA.
64. Wong C.M., Ko Y., Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 2008, 42(12):1737-1748.
65. Handley L.I., Warholak Jackson T.L., Jackson T.R. An evaluation of the validity of inferences made from 3 diabetes assessment instruments: a Rasch analysis. Res Social Adm Pharm 2008, 4:67-81.
66. Chang L. Connotatively inconsistent test items. Appl Meas Educ 1995, 8(3):199-209.
67. Yamaguchi J. Positive vs. negative wording. Rasch Meas Trans 1997, 11(2):567.